comparemela.com

Page 14 - Epidermal Growth Factor Receptor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Tagrisso plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial

Results support potential for a new treatment option that builds on the benefit of first-line standard of care Tagrisso monotherapy Positive high-level results from the FLAURA2 Phase III trial. | May 17, 2023

United statesUnited kingdomDaiichi sankyoAstrazeneca tagrissoAdrian kempSusan galbraithCompany on twitter astrazenecaLung ambition allianceArchives pathology labWorld health organisationLungevity foundationDana farber cancer instituteSingle institution studyInternational agency for research on cancerInvestor relations teamFarber cancer institute

TAGRISSO® (osimertinib) plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial

Results support potential for a new treatment option that builds on the benefit of first-line standard of care TAGRISSO monotherapy . | May 17, 2023

United kingdomUnited statesSusan galbraithDaiichi sankyoArchives pathology labDana farber cancer instituteWorld health organizationSingle institution studyLung ambition allianceLungevity foundationInternational agency for research on cancerExecutive vice presidentPrescription informationPatient informationSouth americaRare diseases

HBM Healthcare Investments year-end results 2022/2023

HBM Healthcare Investments AG / Key word: Personnel HBM Healthcare Investments year-end results 2022/2023 12-May-2023 / 06:30 CET/CEST Release of an ad hoc announcement pursuant to Art. 53. | May 12, 2023

Hong kongSwixx biopharmaArrivent biopharmaBiohaven pharmaceuticalsDrug administrationCathay biotechY mabs therapeuticsMineralys therapeuticsAcrivon therapeuticsTurning point therapeuticsSierra oncologyHarmony biosciencesMonte rosa therapeuticsEpidermal growth factor receptorShareholder meetingAnnual report

Transforming oncology with antibody therapeutics

Janssen EMEA Therapeutic Area Lead for Oncology discusses the potential of BsMAbs like amivantamab to address unmet needs in NSCLC treatment.

Byoung chulMartin vogelJanssen europePersonalized medicine coalitionEuropean lung cancer congressDrug administrationTherapeutic area leadTherapeutic area lead oncologyEpidermal growth factor receptorMesenchymal epithelial transition factorBispecific antibodyEnable multiple mechanismsBroad clinicalClinical lung

Meaningful new treatment option for metastatic colorectal cancer

Results from a multinational trial of trifluridine/tipracil, known as Lonsurf, with or without bevacizumab in refractory metastatic colorectal cancer (mCRC) have resulted in statistically significantly and clinically meaningful improvements.

Josep taberneroMarwan fakihDrug administrationHebron university hospitalEastern cooperative oncology groupEuropean medicines agencyEpidermal growth factor receptorNew england journalTaiho oncologyPriority reviewPrescription drug user fee actClinical developmentPreclinical researchDrug deliveryAtient centricityLinical evolution

vimarsana © 2020. All Rights Reserved.